Paediatrics
Kawasaki Disease
Diagnostic criteria, IVIG + aspirin therapy, echo for coronary artery aneurysms, refractory disease management.
Source: AHA 2017 Kawasaki; RCPCH
Step 1 of ~4
info
Diagnostic Criteria
Fever ≥5 days + ≥4 of 5 principal features: bilateral non-purulent conjunctival injection; mucous membrane changes (red cracked lips, strawberry tongue, oropharyngeal injection); peripheral extremity changes (erythema/oedema/desquamation); polymorphous rash; cervical lymphadenopathy ≥1.5 cm. Atypical/incomplete: fever ≥5 days + 2–3 features + supportive labs. Most common <5y. Verify all paediatric drug doses against a children's formulary.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Dimethyl Fumarate · Disease-Modifying Therapy — Relapsing-Remitting Multiple Sclerosis
- Natalizumab · Disease-Modifying Therapy — MS (Anti-VLA-4 Monoclonal Antibody)
- Interferon Beta-1a · Disease-Modifying Therapy — MS (Interferon)
- Ocrelizumab · Multiple Sclerosis — Disease-Modifying Therapy
- Fingolimod · Multiple Sclerosis — Disease-Modifying Therapy
- Alemtuzumab · Multiple Sclerosis — Disease-Modifying Therapy
Decision support only. Always apply local guidelines and clinical judgement.